Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

DAHANCA 30: A Randomized Non-inferiority Trial of Hypoxia-profile Guided Hypoxic Modification With Nimorazole During Radiotherapy/Chemoradiotherapy of Squamous Cell Carcinoma of the Head and Neck.

NCT02661152 is registered in ClinicalTrials.gov with Danish Head and Neck Cancer Group as lead sponsor.

NCT NCT02661152
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02661152 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
DAHANCA 30: A Randomized Non-inferiority Trial of Hypoxia-profile Guided Hypoxic Modification With Nimorazole During Radiotherapy/Chemoradiotherapy of Squamous Cell Carcinoma of the Head and Neck.
Lead sponsor
Danish Head and Neck Cancer Group
Phase
Phase 3
Overall status
Unknown status
Start date
September 30, 2016
Completion date
December 31, 2023
Enrollment
1,252 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

gene profile, gene signature, head and neck squamous cell carcinoma, hypoxia, hypoxic modification, radiotherapy